NCT06904287 Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
| NCT ID | NCT06904287 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Wake Forest University Health Sciences |
| Condition | Migraine |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-12-16 |
| Primary Completion | 2027-06 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The purpose of this research study is to find out if using magnesium in addition to prochlorperazine will help reduce your migraine pain.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years or older * Able to provide informed consent * English speaking * Primary diagnosis of migraine. Patient with a previous diagnosis of migraine, who experience headaches with typical migraine features (e.g at least 2-3 of the following: recurrent, unilateral, pounding or throbbing in nature, associated with nausea), AND with a clinical exclusion of migraine mimics Exclusion Criteria: * Pregnancy defined as a positive urine HCG * Allergy or sensitivity to study drug * Stated history of renal insufficiency * Documented history of myasthenia gravis * Consumption of study drug within 48 hours prior to enrollment * Previously enrolled in this trial during a different patient encounter
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.